CIBC Private Wealth Group
VIR icon

CIBC Private Wealth Group’s Vir Biotechnology VIR Stock Holding History

CIBC Private Wealth Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$139 Buy
+23
New +$137 ﹤0.01% 3272

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GP
GSK plc London $602M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

CIBC Private Wealth Group's VIR Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Vir Biotechnology (VIR) in Q4 2025: 23 shares worth $139. The stake represents ﹤0.01% of the portfolio and ranks #3272 among its holdings.

218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

  • CIBC Private Wealth Group held 23 shares of Vir Biotechnology worth $139 as of Q4 2025.
  • Vir Biotechnology was a new CIBC Private Wealth Group position in Q4 2025.
  • Vir Biotechnology made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #3272 holding.
  • 218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.